The protein product of the tumor suppressor gene p53 is phosphorylated on multiple residues by several protein kinases. Using a battery of 10 antibodies developed against dierent phosphorylated and acetylated residues of p53, we compared the pattern of p53 phosphorylation and acetylation in tumor-derived cell lines, tumor samples, and non-neoplastic cells. Irrespective of tumor types or the presence of p53 mutation, phosphorylation and acetylation of p53 was substantially higher in samples obtained from tumor tissues than those found in non-transformed samples. Among the 10 sites analysed, phosphorylation of residues 15, 81, 392, and acetylation were among the more frequent modi®cations. Analysis of two of the more abundant phosphorylation or acetylation sites on p53 is sucient to detect 72% of tumor-derived p53 proteins. The distinct pattern of p53 phosphorylation and acetylation in human tumors may oer a new means to monitor the status and activity of p53 in the course of tumor development and progression. Oncogene (2001) 20, 3341 ± 3347.
Introduction
The p53 tumor suppressor gene encodes a short-lived transcription factor (Ko and Prives, 1996; Reich et al., 1983) , which is tightly controlled in response to a variety of stresses through a series of post-translational modi®cations including multi-site phosphorylation and acetylation (for reviews, see Giaccia and Kastan, 1998; Meek, 1999; Prives and Hall, 1999) . Seven serines (6, 9, 15, 20, 34, 37, 46) and two threonines (55, 81; Gatti et al., 2000; Buschmann et al., 2001) in the amino terminal domain, and ®ve serines (315, 372, 376, 378, 392) in the carboxyl-terminal domain were shown to be phosphorylated, and Lys320, Lys373 and Lys382 in the carboxyl-terminal domain can be acetylated (Gu and Roeder, 1997; Sakaguchi et al., 1998; Liu et al., 1999) . Antibodies that recognize speci®c phosphorylated sites on p53 were developed, and studies with these antibodies have demonstrated that in most cases these sites are phosphorylated in response to stress or DNAdamage (Shieh et al., 1997; Bulavin et al., 1999; Higashimoto et al., 2000; Canman et al., 1998; Meek 1998; Oda et al., 2000) . Exceptions include Ser378, which has been shown to be constitutively phosphorylated, and Ser376, which is dephosphorylated in response to DNA damage (Waterman et al., 1998) . Post-translational modi®cations of p53 by phosphorylation and acetylation have been implicated in its stabilization and transcriptional activation (Meek, 1998) . More than 10 kinases were shown to contribute to the phosphorylation of the p53 protein. Within the amino-terminal domain, ATM and Chk2 cause p53 phosphorylation on amino-terminal residues 15 and 20, respectively (Banin et al., 1998; Canman et al., 1998; Hirao et al., 2000) . Casein Kinase I (CKI) was shown to phosphorylate p53 on aa 18 , and DNA ± PK has been implicated in the phosphorylation of p53 on Ser15 and Ser37 (Shieh et al., 1997; Lees-Miller et al., 1992) . The MAPK p38 was shown to phosphorylate p53 at residues 46 and 389 (Bulavin et al., 1999; Huang et al., 1999) , and JNK phosphorylates p53 on aa 81 (Buschmann et al., 2001) . Additional serines at position 6, 9 and 125 of p53 appear to be phosphorylated (Buschmann et al., 2000a; Higashimoto et al., 2000) although the nature of the kinases is yet to be identi®ed. Within the carboxyl terminus, kinases implicated in p53 phosphorylation include CK2, which phosphorylates p53 on residue 392 (Wagner et al., 1998) and CDK, which phosphorylates aa 315 (Price et al., 1995) . In addition, acetylation of Lys320 by PCAF, and Lys373 and/or Lys382 by p300/CBP, is also thought to contribute to the activation of p53 transcriptional activities in response to DNA damage (Gu and Roeder, 1997; Sakaguchi et al, 1998; Liu et al., 1999) . Furthermore, phosphorylation of N-terminal serines 15, 33 and 37 has been proposed to permit subsequent modi®cation of the distant C-terminal lysine residues through enhanced recruitment of p300/CBP/ PCAF (Lambert et al., 1998; Sakaguchi et al., 1998) . Although ample reports point to the complex pattern of p53 phosphorylation, the requirement(s) and regulation of such phosphorylation are not well understood.
Under non-stressed normal growth conditions, p53 is found to exhibit altered phosphorylation patterns at dierent phases of the cell cycle (Buschmann et al., 2000a) . Whereas acetylated at G 0 , p53 was found to exhibit phosphorylation on residues 15, 20, and 372 at the G 1 phase of the cell cycle and on aa 37 and 392 during the G 2 M phase of the cell cycle. Altered phosphorylation patterns were associated with the nature of p53-bound proteins. Whereas in G 0 , p53 was found in complex with JNK, in G 2 M it was associated with Mdm2, p300 and p14 ARF (Buschmann et al., 2000a) . In response to stress, p53 undergoes rapid phosphorylation on several residues, including Ser 6, 9, 20, 37, 46, 81, 389 and 392 . At later time points following DNA damage, p53 is phosphorylated on residues 15 and 372 (Buschmann et al., 2000a) . Changes in the phosphorylation of p53 on residues 18, 20, 46, 81 and 389 has been implicated so far in p53 stabilization and transcriptional activities (Banin et al., 1998; Hirao et al., 2000; Sakaguchi et al., 1998; Shieh et al., 1997; Bulavin et al., 1999; Huang et al., 1999; Buschmann et al., 2000a) .
Mutations in p53 were reported in over 50% of human tumors (Hollstein et al., 1991; Gualberto et al., 1998) . Whereas in most cases mutant p53 has lost its transcriptional activities (Ko and Prives, 1996; Reich et al., 1983; Hall et al., 1993) , selected p53 mutants transcriptionally activate a dierent subset of target genes through which they elicit a gain of function phenotype (Lanyi et al., 1998) . Greater stability is characteristic of most mutant forms of p53. The latter can be attributed to altered association of mutant p53 with proteins implicated in its degradation and stabilization (Buschmann et al., 2000b) . Changes in mutant p53 association and consequently p53 stability and activities can, in part, be attributed to altered conformation, which has been demonstrated for several of p53 hot spot mutants (Foster et al., 1999) . In addition, growing evidence suggests that a portion of wild type forms of p53 that are expressed in a variety of human tumors do not exhibit the same degree of transcriptional activity often found in the wild type counterpart in non-transformed tissues (Bullock et al., 1997; Satyamoorthy et al., 2000) .
The extensive changes seen in p53 phosphorylation during cell cycle progression led to the hypothesis that tumors may exhibit a dierent phosphorylation pattern of p53, either because of the presence of a mutation, or because of deregulated kinases and phosphatases. In this study we compared the pattern of p53 phosphorylation in tumor-and non-transformed-derived cell lines and tissues. We demonstrate that, in tumors, mutant as well as wt p53 exhibits a distinct pattern of phosphorylation when compared with p53 expressed in non-transformed cells. The possible implication of using altered p53 phosphorylation for monitoring p53 status and activities is discussed.
Results

Phosphorylation of mutant p53 in tumor-derived cell cultures
To determine the pattern of mutant p53 phosphorylation and acetylation in tumor-derived cell lines under normal growth conditions we analysed 18 cell lines with de®ned p53 mutations. Cell lines used for phospho-analysis were derived from seven tumor types and included a total of nine dierent mutations. Several tumor-derived cell lines with the same hot spot mutation (R248W or R273H) were included in this analysis to enable comparison of the phosphorylation pattern among dierent tumors that have the same mutation. As controls for this analysis, we used two non-transformed ®broblast cell lines (GM00038 and TIG) known to harbor wild type p53. Additional analysis has been carried out in parallel on tumorderived tissues and cell lines that harbor wild type p53, thus allowing comparison of the phosphorylation pattern of wild type and mutant forms of p53 within the tumor environment. Given the changes in the level of p53 expression in human tumors, our analysis has always relied on normalized levels of p53 expression (see Materials and methods). Figure 1a depicts a representative immunoblot analysis for the phosphorylation pattern of mutant p53 from four tumor-derived cell lines. This analysis, which represents nine dierent phosphorylation and three acetylation sites, reveals the dierences in levels of phosphorylation among the dierent tumors and respective phospho-acceptor sites. The results of this, and 14 additional tumors, are summarized in Table 1 . While depicting the wide range of phosphorylation intensities among the dierent tumors, this analysis allows us to conclude that among the phosphoacceptor and acetylation sites, the most frequently and intensively phosphorylated sites (marked ++, +++ which represents an over twofold increase in phosphosignal) include Ser15, Thr81, Ser392 and p53 acetylation on either 320, 373, 382 or their combinations (our analysis cannot distinguish between the three acetylation sites).
As the current study relies on the use of phosphospeci®c antibodies, which are expected to have varying degrees of sensitivity, we consider the possibility that residues that were not recognized by the speci®c phospho-antibodies may still be phosphorylated, albeit at very low levels. To minimize such possibility each analysis was also performed via immunoprecipitation and Westerns, in which higher amounts of p53 were used (not shown). Based on these analyses we concluded that lack of signal should be attributed to the lack of intrinsic phosphorylation rather than the poor sensitivity of the respective antibody used. Given that the analysis was carried out on mutant p53 that was obtained from nine dierent tumor types, we assessed whether it is possible to establish a phosphorylation pattern that would be tumor typespeci®c. Our results do not support the existence of a tumor type-speci®c phosphorylation pattern.
Since the analysis included multiple tumors, which carry the same hot spot mutation (three tumors with hot spot 248 R ± W and eight tumors with hot spot 273 R ± H mutations), we also assessed the possible link between a speci®c mutation and phosphorylation pattern. Among the eight tumors that harbor hot spot 273 mutation we could not identify a common phosphorylation pattern; similarly, there was no unifying pattern for the three tumors that harbor a 248 mutation. These observations suggest that the phosphorylation pattern re¯ects neither the tumor type nor the mutation type. We next assessed whether any of the phosphoacceptor sites could be used to identify p53 from human tumors, as compared to wt p53 in normal tissues or non-transformed cell lines. As shown in Table 2 , p53 from 450% of human tumors could be identi®ed based on elevated phosphorylation on residues 15 or 81, or acetylation. A combination of two sites among Figure 1 (a) Phosphorylation of mutant p53 in tumor-derived cell lines. Normal human ®broblasts (TIG) at early passage (24 ± 27) and tumor-derived cell lines were maintained in DMEM supplemented with 10% fetal bovine serum, and antibiotics. Cell pellet was lysed with three packed volumes of phospho-extraction buer (20 mM Tris-HCl, pH 7.5, 20 mM p-nitrophenylphosphate, 1 mM EGTA, 50 mM sodium¯uoride, 50 mM sodium orthovanadate, 5 mM benzamidine, 100 mM NaCl, 5 mM MgCl 2 , supplemented with 40 mg/ml Dnase I and 1 mg/ml protease inhibitors) and incubated for 10 min at RT. Following incubation with sample-buer for 5 min at 958C, samples (100 mg) were loaded and separated on a 10% SDS ± PAGE and electroblotted for 3 h at 100 V. The initial set of Westerns was carried out using pAb421 antibodies (Oncogene) and revealed the relative amount of p53 in each of the samples. According to the level of p53 seen in these sets of Westerns (which were also monitored via densitometric analysis) we have run a second set of Westerns in which levels of proteins loaded was adjusted to results in equal levels of p53. Normalization of p53 expression levels is essential in assessing possible changes in the level of p53 phosphorylation. Following con®rmation that equal levels of p53 are seen, the same conditions were applied for all subsequent phospho-p53 analysis. The membrane was incubated overnight with respective acetylation or phospho-antibodies (1 : 1000; NEB) and developed, using ECL detection (Amersham). Following detection of the phosphorylated signal the membrane was stripped and re-probed with antibodies pAb421 to p53 (bottom panel). Each of the analyses was performed in duplicate. Densitometric measurements were performed on each of the membranes and evaluated using the BIO-RAD GS710 Calibrated Imaging Densitometer and the Quantity One Software. (b) Phosphorylation of wt p53 in normal human ®broblasts and tumor-derived cell lines. Proteins were prepared from the indicated cell lines, as well as from UV-treated normal human ®broblasts as a positive control. Position of his-tagged bacterially produced p53 is shown. Analysis of p53 phosphorylation and expression levels was carried out as indicated in legend to Figure 1 . Data shown represents three independent analyses the better-modi®ed residues increases the sensitivity of tumor p53 detection up to 78% (Table 2) . Importantly, the speci®city of this detection, which allows us to distinguish the tumor samples from normal tissues, is between 80 ± 100% ( Table 2) .
Phosphorylation of wt p53 in tumor-derived cell cultures
Parallel to the analysis of mutant p53 in tumor-derived cell lines, we performed an analysis of wt p53 in nine human melanoma-derived cell lines. The latter analysis enables us to determine whether the pattern of mutant p53 phosphorylation, as re¯ected in Table 1 , could be attributed to the mutation per se or alternatively, to other epigenetic changes, (i.e. kinase or phosphatase activities) which have been reported to undergo changes in various human tumors (Fernandez et al., 1998) . The analysis of wt p53 in non-neoplastic human ®broblastic cells revealed a very weak level of phosphorylation, which is limited to a few residues (Table 1) . Conversely, the wt p53 in human tumors was found to exhibit a substantially greater degree of phosphorylation on multiple residues (Figure 1b and Table 3) . A relatively high level of phosphorylation in at least four phosphoacceptor sites was observed in seven out of nine tumor cell lines containing wt p53, when compared with wt p53 in non-transformed human ®broblasts (Table 3 ). The highest and most frequent phosphorylated residues are serines, 6, 15, 37 and threonine 81. The nature of the dierent degree of wt p53 phosphorylation as found in two out of the nine tumor-derived cell lines studied here, A549, and A875, which show weak phosphorylation similar to that found in the NHF, is yet to be determined. In most human melanoma-derived cell lines the pattern of wt p53 phosphorylation resembles the extensive phosphorylation found in mutant p53 expressing tumor cells. These observations imply that wt p53, which exhibit extensive phosphorylation as found on mutant p53 from tumors, may be non-functional. Consistent with this possibility is the recent study of Halazonetis and colleagues, who demonstrated that wt p53 is not functional in human melanomas (Satyamoorthy et al., 2000) . These data further suggest that the increase in the complexity of p53 phosphorylation cannot be solely attributed to sequence status but rather to the altered activity of respective kinases or phosphatases in the tumor tissues.
Phosphorylation of mutant p53 in tumor-derived tissue samples
Important con®rmation of the pattern of p53 phosphorylation in human tumor-derived cell lines comes from the analysis of tumor and non-transformed samples obtained from freshly dissected tumors and normal appearing neighboring tissues revealed that the tumor samples exhibit a substantially greater degree of p53 phosphorylation, regardless of the status of p53 (wt or mutant), when compared with the nontransformed samples (data not shown). These ®ndings suggest that the mutant form of p53 is indeed subject to a more extensive phosphorylation in the tumor tissue. Two of the three tumors that harbor a wild type Analysis of wt p53 phosphorylation in tumor-derived cell lines was carried out on indicated sites. Data shown re¯ect Western blot analysis performed in duplicate on each of the indicated cell lines. The degree of phosphorylation was normalized to the amount of p53 expressed and quanti®ed with a densitometer. Relative changes in the degree of p53 phosphorylation (described in detail in Table 1 ) are indicated (7, +, ++ or +++) Figure 2 Phosphorylation of p53 in samples derived from freshly dissected tumor and neighboring normal tissues. Tumors and normal tissues that are distant to the tumor site were obtained from the surgical material of six patients with colorectal cancer, ages 44 ± 77. Samples # 31, 34, 35 and 37 were diagnosed as stage II, Duke's stage B, whereas samples 32 and 33 were categorized as stage IV and III, respectively, Duke's stage C. Samples were frozen on dry ice immediately after removal. Tumor samples #31, 32 and 37 harbored mutant p53. Tumor and normal tissues were homogenized in liquid nitrogen and powdered tissues were lysed in phospho-extraction buer as indicated in legend to Figure 1 . Protein samples were equilibrated to achieve equal levels of p53 before separation on a 10% SDS ± PAGE and electroblotted for 3 h at 100 V. The membrane was incubated overnight with respective acetylation or phospho-antibodies (1 : 1000) and developed, using ECL detection. Phosphorylation of p53 at the indicated residues was performed as detailed in the legend to Figure 1 . Exposure times of the membranes containing the normal tissue material were 20 times longer than those required for the detection of signal from the tumor-derived proteins form of p53 exhibited a weak phosphorylation signal, thus resembling two of the 9 tumor-derived cell lines which harbor wt p53 (A875 and A549 lines in Figure  1b and Table 3 ).
Discussion
The analysis of p53 phosphorylation via phosphoantibodies directed to dierent phosphoacceptor sites has revealed a marked increase in the degree of p53 phosphorylation in tumor derived cell lines as well as in freshly processed tumor tissues. Conversely, nontransformed cell cultures and normal tissues obtained from sites distant to the tumor tissues revealed a very weak level of p53 phosphorylation. Surprisingly, the high level of p53 phosphorylation was not limited to the tumors bearing mutant forms of p53, as it was also observed at high frequency in tumors bearing the wt form of p53. The existence of a high level of p53 phosphorylation in human tumors explains in part why we could not distinguish the pattern of p53 phosphorylation among dierent tumor types or mutant forms of p53. Among possible mechanisms that may account for a greater level of p53 phosphorylation in human tumors, regardless of the nature of p53 status, are altered activities of p53 kinases and phosphatases. Given the large number of kinases implicated in the phosphorylation of p53, and the ability of more than one kinase to phosphorylate almost any given site, it would be necessary to carefully evaluate each kinase in a tissue-and tumorspeci®c manner. The nature of the current complexity may also stem from the possibility that p53 phosphorylation may occur in a sequential fashion; along this hypothesis, phosphorylation on selective residues may trigger subsequent phosphorylation on other sites. Accordingly, it is possible that the primary phosphorylation is not properly controlled in tumor tissues, an event that would be sucient to trigger the extensive phosphorylation on other residues. Since the nature of the extensive phosphorylation is so wide, and is not aected by the position of mutations, some of which alters p53 conformation, it may be possible to predict which of the phosphoacceptor sites is less susceptible for conformation-dependent modi®cations, thereby pointing to the putative triggering signal. Our ®ndings point to a general switch in the regulation of p53 phosphorylation, which takes place during tumor development and/or progression. Further studies will be required to assess at what stage of tumor development such changes occur. The similar pattern of extensive wt and mutant p53 phosphorylation seen in human tumor-derived tissues and cell lines may also point to a mechanism by which activities of wt p53 are often impaired in human tumors. Along these lines, the extensive degree of p53 phosphorylation is expected to yield altered conformation and consequently in the association with proteins dierent from those that would bind to the weakly phosphorylated form of p53. Corresponding changes are expected to include altered stability, which has been widely reported, as changes in the localization of p53 within nuclei/nucleoli, and its ability to elicit transcriptional activation or suppression.
The analysis performed here on over 10 dierent sites for phosphorylation and acetylation may not always be required to ascertain the phospho-status of p53. It may be sucient to analyse only selective sites to eciently identify tumors where p53 is hyperphosphorylated. Among the sites found as most frequently modi®ed are residues 15, 81 and residues that undergo acetylation. Further large-scale and functional analysis of both normal and tumor tissues which harbor wt and mutant forms of p53 is necessary to assess the possible diagnostic and therapeutic implications of the extensive p53 phosphorylation in human cancers.
Materials and methods
Cells and tissues
Normal human ®broblasts (TIG) at early passage (24 ± 27) and tumor-derived cell lines were maintained in DMEM supplemented with 10% fetal bovine serum, and antibiotics. Tumors and normal tissues that are distant to the tumor site were obtained from the surgical material of six patients with colorectal cancer, ages 44-77. Samples # 31, 34, 35 and 37 were diagnosed as stage II, Duke's stage B, whereas samples 32 and 33 were categorized as stage IV and III, respectively, Duke's stage C. Samples were frozen on dry ice immediately after removal.
Western blot procedure for phospho-antibodies
Cell pellet was lysed with three packed volumes of phosphoextraction buer (20 mM Tris-HCl, pH 7.5, 20 mM pnitrophenylphosphate, 1 mM EGTA, 50 mM sodium¯uoride, 50 mM sodium orthovanadate, 5 mM benzamidine, 100 mM NaCl, 5 mM MgCl 2 , supplemented with 40 mg/ml DNaseI and 1 mg/ml protease inhibitors) and incubated for 10 min at RT. Following incubation with sample-buer for 5 min at 958C, samples (100 mg) were loaded and separated on a 10% SDS ± PAGE and electroblotted for 3 h at 100 V. Preliminary Western blot analyses were carried out using pAb421 antibodies (Oncogene) to detect relative p53 amount in respective cell lines. P53 levels were evaluated by densitometric measurement. For all further experiments equal p53 amounts of investigated cell lines were loaded on the gels, based on the above described densitometric evaluations. The membrane was incubated overnight with respective acetylation or phospho-antibodies (1 : 1000; NEB) and developed, using ECL detection (Amersham).
Preparation of phospho lysates from normal and tumor tissues
Tumor and normal tissues were homogenized in liquid nitrogen and powdered tissues were lysed in phosphoextraction buer as indicated above. Protein samples with equilibrated p53 amount (described above) were separated on a 10% SDS ± PAGE and electroblotted for 3 h at 100 V. The membrane was incubated overnight with respective acetylation or phospho-antibodies (1 : 1000) and developed, using ECL detection. 
Densitometric measurements
For densitometric measurements three independent experiments for each antibody analysis were evaluated using the BIO-RAD GS710 Calibrated Imaging Densitometer and the Quantity One Software.
